Abbott and Fujirebio partner on development of Research Use Only Neurofilament-light Chain (Nf-L) neurology biomarker assay for Abbott’s Alinity® i

Company news
  • Parties are seeking to make the Nf-L research use only assay for Abbott’s Alinity i available by 2025
  • Assay can be used to support studies for Nf-L’s utility in a variety of neurological diseases

ABBOTT PARK, Ill., MALVERN, PA & TOKYO, JAPAN, Feb. 12, 2024 – Abbott and Fujirebio announced today a partnership to develop a research use only (RUO) neurofilament-light chain (Nf-L) neurology biomarker assay for use on Abbott’s Alinity® i. Abbott will make the RUO assay available to researchers conducting studies demonstrating the utility of the Nf-L biomarker. Research with the Nf-L biomarker is ongoing in a variety of neurological diseases including multiple sclerosis, Alzheimer’s, traumatic brain injury and cognitive impairment. Abbott and Fujirebio are seeking to make the Nf-L research use only assay for Abbott’s Alinity i available by 2025.

“Bringing Nf-L to Alinity i will allow researchers to benefit from the ease and functionality of Abbott’s Alinity i instruments, which are available in labs across the U.S.,” said Beth McQuiston, M.D., medical director in Abbott’s diagnostics business and board-certified neurologist. “Biomarkers are playing a critical role in how we identify and treat diseases and having the appropriate testing technology will help support and advance neuroscience research.”

“This continued partnership with Abbott is an essential step in our mission to bring a higher standard of care to patients and their families in the battle against neurodegenerative diseases,” said Monte Wiltse, president and chief executive officer, Fujirebio Diagnostics, Inc.

The Nf-L assay is the first RUO assay Abbott is bringing to the Alinity i system. Abbott is exploring research use pathway for other new biomarkers to support the research community with new RUO assays on its Alinity i system -- allowing for the faster development of diagnostics and therapeutics.

About Alinity:
Abbott's Alinity family of harmonized solutions is unprecedented in the diagnostics industry, working together to address the challenges of using multiple diagnostic platforms and simplifying diagnostic testing. Alinity systems are designed to be more efficient – running more tests in less space, generating test results faster and minimizing human errors – while continuing to provide quality results. The availability of the Alinity systems and tests varies by geography. More information is available at

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. 

About Fujirebio:
Fujirebio, a member of H.U. Group Holdings Inc., is a global R&D-driven company focused on developing novel in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Fujirebio has a longstanding partnership of contract development and manufacturing with Abbott. We value partnerships with leading companies in the industry, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms. For more information about Fujirebio, please visit


Abbott Media:
Kim Modory, 224-668-4696 

Abbott Investor Relations:
Ryan Aliff, 224-667-2299


H.U. Group Holdings/Fujirebio Media:
Public Relations Section, Public Relations and Sustainability Dept.
Phone: +81-3-6279-0884; Email:

H.U. Group Holdings/Fujirebio Investor Relations:
IR/SR Dept.
Phone: +81-3-6279-0926; Email: